The GLP is committed to full transparency. Download and review our Annual Report.

How evolutionary theory may complicate CRISPR as cancer fighting tool

| | September 16, 2016

Using guide RNAs, CRISPR-Cas9 can target and inactivate any gene in a living cell. That makes a powerful tool for loss-of-function analyses of particular genes’ roles in disease.

But CRISPR-Cas9’s promise becomes less certain when it comes to cancers, [Ewald] cautioned.

[In addition, o]ne concern is the fact that genes are frequently pleiotropic, affecting multiple molecular pathways. Just because a gene promotes tumor growth does not imply that it lacks other, beneficial effects.

[“]But the problem is that if you’re putting a gene into an organism that has undergone evolutionary selection pressures that have adjusted all of a gene’s pleiotropic effects, then you affect those, too,” Ewald cautioned.

It is open to question, however, whether the next big genome-editing breakthrough will come from systemically screening natural CRISPR and CRISPR-like systems.

“It is certainly hard to predict whether new gene editing systems will emerge from very broad studies of natural CRISPR systems,” Dr. [Dana] Carroll said. “I’m sure additional variants will turn up, but perhaps nothing dramatically different from what we’ve seen already.”

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis. Read full, original post: The Evolutionary Implications of CRISPR-Cas9 for Clinical Oncology

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend